MET and urinary bladder cancer: In human bladder cancer, c-MET has been shown to promote disease progression by transactivating the expression of AXL and PDGFR-α via MEK/ERK1/2 signaling, independent of Ras and Src.202 Similarly, in triple-negative breast cancer cells, AXL interacts with other ErbB receptor family members, c-MET, and PDGFR contributing to resistance against EGFR TKIs.221